Travere Therapeutics (TVTX) Stock Forecast & Price Target

Compare

506 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TVTX Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Travere

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TVTX Stock 12 Month Forecast

Average Price Target

$34.14

▲(101.89% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $34.14 with a high forecast of $47.00 and a low forecast of $20.00. The average price target represents a 101.89% change from the last price of $16.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","18":"$18","28":"$28","38":"$38","48":"$48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18,28,38,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,18.043076923076924,20.456153846153846,22.869230769230768,25.28230769230769,27.69538461538461,30.108461538461537,32.52153846153846,34.934615384615384,37.347692307692306,39.76076923076923,42.17384615384615,44.58692307692307,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,17.053846153846155,18.47769230769231,19.90153846153846,21.325384615384614,22.74923076923077,24.173076923076923,25.596923076923076,27.020769230769233,28.444615384615382,29.86846153846154,31.292307692307695,32.716153846153844,{"y":34.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.63,15.966153846153848,16.302307692307693,16.638461538461538,16.974615384615387,17.310769230769232,17.646923076923077,17.983076923076922,18.31923076923077,18.655384615384616,18.99153846153846,19.327692307692306,19.663846153846155,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.57,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$34.14

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$18

Hold

6.45%

Upside

Reiterated

08/07/25

Travere Therapeutics' stock score is driven by strong commercial performance and positive regulatory developments for FILSPARI, despite financial instability and valuation concerns. The technical indicators suggest bullish momentum, but profitability challenges and high leverage pose significant risks.

Edward NashCanaccord Genuity

Canaccord Genuity

$47

Buy

177.94%

Upside

Reiterated

08/08/25

Allison BratzelPiper Sandler

Piper Sandler

$25

Hold

47.84%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

Joseph SchwartzLeerink Partners

Leerink Partners

$42

Buy

148.37%

Upside

Reiterated

08/07/25

Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics

Laura ChicoWedbush

Wedbush

$30→$32

Buy

89.24%

Upside

Reiterated

08/07/25

Travere Therapeutics price target raised to $32 from $30 at WedbushTravere Therapeutics price target raised to $32 from $30 at Wedbush

Greg HarrisonScotiabank

Scotiabank

$30→$31

Buy

83.32%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$23→$20

Hold

18.27%

Upside

Reiterated

08/07/25

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), OmniAb (NASDAQ: OABI) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$30

Buy

77.41%

Upside

Reiterated

08/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: REPRO-MED Systems (NASDAQ: KRMD) and Travere Therapeutics (NASDAQ: TVTX)

Jason ZemanskyBank of America Securities

Bank of America Securities

$28→$27

Buy

59.67%

Upside

Reiterated

08/06/25

Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities

Tyler Van BurenTD Cowen

TD Cowen

$30

Buy

77.41%

Upside

Reiterated

08/06/25

Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics

Vamil DivanGuggenheim

Guggenheim

$47

Buy

177.94%

Upside

Reiterated

07/01/25

Guggenheim Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Liisa BaykoEvercore ISI

Evercore ISI

$45

Buy

166.11%

Upside

Reiterated

06/16/25

Evercore ISI Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Yigal NochomovitzCiti

Citi

$35→$32

Buy

89.24%

Upside

Assigned

06/10/25

Buy Rating for Travere Therapeutics: Anticipated FDA Approval and Strategic Developments Signal Significant Upside Potential

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

05/16/25

Cantor Fitzgerald reiterates Overweight Rating on Travere Therapeutics (TVTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Travere Therapeutics (NASDAQ: TVTX).

Anupam RamaJ.P. Morgan

J.P. Morgan

$44→$43

Buy

154.29%

Upside

Reiterated

05/16/25

Travere Therapeutics (TVTX) PT Lowered to $43 at JPMorganJPMorgan analyst Anupam Rama lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $43.00 (from $44.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$18

Hold

6.45%

Upside

Reiterated

08/07/25

Edward NashCanaccord Genuity

Canaccord Genuity

$47

Buy

177.94%

Upside

Reiterated

08/08/25

Allison BratzelPiper Sandler

Piper Sandler

$25

Hold

47.84%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

Joseph SchwartzLeerink Partners

Leerink Partners

$42

Buy

148.37%

Upside

Reiterated

08/07/25

Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics

Laura ChicoWedbush

Wedbush

$30→$32

Buy

89.24%

Upside

Reiterated

08/07/25

Travere Therapeutics price target raised to $32 from $30 at WedbushTravere Therapeutics price target raised to $32 from $30 at Wedbush

Greg HarrisonScotiabank

Scotiabank

$30→$31

Buy

83.32%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$23→$20

Hold

18.27%

Upside

Reiterated

08/07/25

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), OmniAb (NASDAQ: OABI) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$30

Buy

77.41%

Upside

Reiterated

08/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: REPRO-MED Systems (NASDAQ: KRMD) and Travere Therapeutics (NASDAQ: TVTX)

Jason ZemanskyBank of America Securities

Bank of America Securities

$28→$27

Buy

59.67%

Upside

Reiterated

08/06/25

Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities

Tyler Van BurenTD Cowen

TD Cowen

$30

Buy

77.41%

Upside

Reiterated

08/06/25

Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics

Vamil DivanGuggenheim

Guggenheim

$47

Buy

177.94%

Upside

Reiterated

07/01/25

Guggenheim Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Liisa BaykoEvercore ISI

Evercore ISI

$45

Buy

166.11%

Upside

Reiterated

06/16/25

Evercore ISI Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Yigal NochomovitzCiti

Citi

$35→$32

Buy

89.24%

Upside

Assigned

06/10/25

Buy Rating for Travere Therapeutics: Anticipated FDA Approval and Strategic Developments Signal Significant Upside Potential

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

05/16/25

Cantor Fitzgerald reiterates Overweight Rating on Travere Therapeutics (TVTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Travere Therapeutics (NASDAQ: TVTX).

Anupam RamaJ.P. Morgan

J.P. Morgan

$44→$43

Buy

154.29%

Upside

Reiterated

05/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

1 Month

xxx

Success Rate

12/18 ratings generated profit

Average Return

+8.52%

reiterated a xxx

rating 13 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +8.52% per trade.

3 Months

xxx

Success Rate

11/18 ratings generated profit

Average Return

+11.57%

reiterated a xxx

rating 13 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +11.57% per trade.

1 Year

Liisa BaykoEvercore ISI

Success Rate

17/29 ratings generated profit

Average Return

+17.10%

reiterated a buy rating 2 months ago

Copying Liisa Bayko's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +17.10% per trade.

2 Years

xxx

Success Rate

12/18 ratings generated profit

Average Return

+48.62%

reiterated a xxx

rating 13 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +48.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVTX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TVTX has received 14 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. TVTX average Analyst price target in the past 3 months is 34.14.

Each month's total comprises the sum of three months' worth of ratings.

TVTX Financial Forecast

TVTX Earnings Forecast

Next quarter’s earnings estimate for TVTX is -$0.27 with a range of -$0.53 to -$0.02. The previous quarter’s EPS was -$0.14. TVTX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year TVTX has Outperformed its overall industry.

TVTX Sales Forecast

Next quarter’s sales forecast for TVTX is $104.28M with a range of $90.54M to $115.30M. The previous quarter’s sales results were $114.45M. TVTX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year TVTX has Outperformed its overall industry.

TVTX Stock Forecast FAQ

What is TVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 34.14.

What is TVTX’s upside potential, based on the analysts’ average price target?

Travere Therapeutics has 101.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TVTX a Buy, Sell or Hold?

Travere Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Travere Therapeutics’s price target?

The average price target for Travere Therapeutics is 34.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $20.00. The average price target represents 101.89% Increase from the current price of $16.91.

What do analysts say about Travere Therapeutics?

Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of TVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Travere Therapeutics (TVTX) Stock Forecast & Price Target

TVTX Analyst Ratings

TVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Travere Therapeutics

TVTX Analyst Recommendation Trends

TVTX Financial Forecast

TVTX Earnings Forecast

TVTX Sales Forecast

TVTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts